Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-06-15
2000-05-16
Wilson, James O.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 2, 514 23, 514 27, 514 46, 536 286, 536 287, 536 291, A61K 31495, C07H 19167
Patent
active
060637722
ABSTRACT:
Ribavirin is administered to a patient in a dosage range which is effective to modulate lymphokine expression In activated T cells. In particular, ribavirin is used to suppress Th2-mediated T cell responses and promote Th1-mediated T cell response. Thus, instead of administering ribavirin in its well-recognized role as an anti-viral agent, ribavirin is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, helminth Infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection.
REFERENCES:
Abonyi, M, et al, Comparative Efficacy of 6 Months Treatment with Interferon Alfa-2b, Ribavirin and Combination Therapy in Chronic Hepatitis C, Progress in Hepato-Pharmacology, 1995, 1:254-261.
Di Bisceglie, AM, et al, A Pilot Study of Ribavirin Therapy for Chronic Hepatitis C, Hepatology 1992, 16:649-654.
Di Bisceglie, AM, et al, Randomized, Double Blind Placebo-Controlled Trial of Ribavirin Therapy for Chronic Hepatitis C, Hepatology, 1993, 18:145.
Di Bisceglie, AM, et al, Randomized, Double Blind Placebo-Controlled Trial of Ribavirin Therapy for Chronic Hepatitis C, Annals of Internal Medicine, 1995, 123:897-903.
Bizollon, T, et al, Ribavirin and Interferon Treatment for Hepatitis C Recurrence Following Orthopic Liver Transplantation, Abstract from the 29th Annual Meeting of the European Association for the Study of the Liver, Sep. 7-10, 1994.
Bizollon, T, et al, New Approaches to the Treatment of Hepatitis C Virus Infection After Liver Transplantation Using Ribavirin, J. of Hepatology, 1995, 23(2):22-25.
Bodenheimer Jr, et al, Tolerance and Efficacy of Oral Ribavirin Treatment of Chronic Hepatitis C: A Multicenter Trial, 1994.
Braconier, JH, et al, Combined Alpha-Interferon And Ribavirin Treatment in Chronic Hepatitis C: A Pilot Study, Scand J Infect Dis, 1995, 27: 325-329.
Brillanti S, et al, Combination Therapy With Ribavirin and .alpha.-Interferon in Patients with Chronic Hepatitis C . . . , AASLD Abstract, 1993.
Brillanti S, et al, A Pilot Study Of Combination Therapy With Ribavirin Plus Interferon Alfa for Interferon Alfa-Resistant Chronic Hepatitis C, Gastroenterology, 1994:107, 812-817.
Brillanti, S, et al, Combination Antiviral Therapy With Ribavirin And Interferon Alfa In Interferon Alfa Relapsers And Non Responders: Italian Experience, Journal of Hepatology, 1995: 23 (2): 13-16.
Brouwer, JT, et al, What Options Are Left When Hepatitis C Does Not Respond to Interferon? Placebo-Controlled Benelux Multicentre Retreatment Trial on Ribavirin Monotherapy Versus Combination with Interferon, Abstract from the Following Orthopic Liver Transplantation, Abstract from the 29th Annual Meeting of the European Association for the Study of the Liver, Sep. 7-10, 1994.
Camps, J, et al, Ribavirin in the Treatment of Chronic Hepatitis C Unresponsive to Alpha Interferon, J. of Hepatology 1993, 19:408-412.
Cattral M, New Approaches to Treatment of Hepatitis C in Transplant Patients and the Canadian Experience, Therapeutic Challenges in HCV: A Symposium During the American College of Gastroenterology Annual Meeting, Sep. 29, 1994, San Francisco Marriott.
Chemello, L, et al, Response to Ribavirin to Interferon and to a Combination of Both in Patients with Chronic Hepatitis C and its Relation to HCV Genotypes, Abstract from the 29th Annual Meeting of the European Association for the Study of the Liver, Sep. 7-10, 1994.
Chemello, L, et al., The Effect of Interferon Alfa and Ribavirin Combination Therapy in Naive Patients with Chronic Hepatitis C, J. of Hepatology, 1995, 23:(2)8-12.
Chossegros, P, et al, In Kidney Graft Recipients Ribavirine Is Able To Reduce HCV Viral Load, (Journal unknown), (date unknown).
Dieterich, DT, et al, Use Of Ribavirin For Recurrent Hepatitis C Virus (HCV) In Liver Transplant Patients After Failure Of Interferon, Abstract Form From American Gastroenterological Association And American Association For The Study Of Liver Diseases, New Orleans, Louisiana, May 15-18, 1994.
Dusheiko, G, et al, Ribavirin Treatment for Patients with Chronic Hepatitis C: Results of a Placebo-Controlled Study, J. of Hepatology, 1996, 25:591-598.
Dusheiko, G, et al, Results Of A Placebo-Controlled Study Of Ribavirin In Patients With Chronic Hepatitis C, Abstract From The 45th Annual Meeting Of The American Association For The Study Of Liver Diseases, Oct. 1994, 440.
El-Zayadi, A, et al, Combination Treatment of Alpha Interferon-2b (alpha IFN) and Ribavirin in Chronic Hepatitis C Genotype 4 Patients Resistant to Interferon Therapy, Hepatology, Abstracts, Oct. 1995, 182.
Gane et al, Ribavirin Therapy for Hepatitis C Infection Following Liver Transplantation, Transpl. Int. 1995, 8:61-64.
Gatell JM, et al, Efficacy of Ribavirin on Hepatitis C Virus Infection in HIV Infected Patients, Abstract from the 32nd ICAAC, Oct. 1992, Anaheim, California.
Grellier, L, et al, CD4 Positive T Lymphocyte Proliferative Responses In A Cohort Of Patients With Chronic Hepatitis C Virus Treated With Ribavirin and Interferon, Hepatology, Oct. 1997, Abstract 1112.
Hoofnagle, JH, et al, Long-Term Therapy with Ribavirin for Chronic Hepatitis C, Abstract Form for Third International Meeting on Hepatitis C Virus and Related Viruses, Marriott Surfers Paradise Resort, Gold Coast Australia, Aug. 28-Sep. 3, 1995.
Hoofnagle, JH et al, Abstract, Abstract From 3.sup.rd Int'l Meeting on Hepatitis C Virus and Related Viruses, 1995.
Hultgren, C, et al, Ribavirin Therapy Shifts the T-Helper 1 (TH1)/TH2 Subset Balance in Vivo, Gastroenterologie Clinique & Biologique: Abstracts Book, (92), Vth International Conference Current Trends in Chronically Evolving Viral Hepatitis, Oct. 1997, Lyon, France.
Kakumu, S, et al, A Pilot Study of Ribavirin and Interferon Beta for the Treatment of Chronic Hepatitis C, Gastroenterology, 1993, 105:507-512.
Koskinas, J, et al, Effects of Ribavirin on Intra- and Extra-Hepatic Replication of Hepatitis C Virus in Interferon.
Non-Responsive tients, International Symposium on Viral titis, Madrid Spain, Feb., 1994.
Lai, M, et al, Combination Therapy of a-Interferon and Ribavirin in Patients with Chronic Hepatitis C: An Interim Report, AASLD Abstracts 93A, Chicago, Nov. 4-7, 1993 (146).
Lai, M, et al, Long-term Efficacy of Ribavirin Plus Interferon Alfa in the Treatment of Chronic Hepatitis C, Gastroenterolgy, 1996, 111:1307-1312.
Lechmann et al, T- and B-Cell Responses to Different Hepatitis C Virus Antigens . . . , Hepatology 1996, 24:790-795.
Ljungman, P, et al, Oral Ribavirin for Prevention of Severe Liver Disease Caused by Hepatitis C Virus During Allogeneic Bone Marrow Transplantation, Clinical Infectious Diseases, 1996, 23:167-169.
Martin et al, Effect of Ribavirin on Peripheral Blood Mononuclear Cells (PBMC) in Patients with Chronic Hepatitis C, Hepatology 1996, 24:394A.
Naoumov, N.V, Host Immune in Responses in Chronic HCV Infection, Gastroenterologie Clinique & Biologique: Abstracts Book 1997, (145) Vth International Conference Current Trends in Chronically Evolving Viral Hepatitis, Oct. 1997, (92) Lyon, France.
Nelson, D, et al, Intrahepatic Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Activity and Response to Interferon Alfa Therapy in Chronic Hepatitis C, Hepatology, 1998, 28:225-230. (Abstract published in 1997).
Ning, Q, et al, Ribavirin Inhibits Viral Induced Macrophage Production of Tumor Necrosis Factor . . . , Hepatology 1996, 24:335A. (abstract published in 1996).
Pol, S, et al, Ribavirin-Interferon vs Interferon (a2b-IFN) Alone in Non-Responders to a-IFN in Chronic Hepatitis C, Hepatology Abstracts, Oct. 1996, (918).
Reichard, O, et al, Ribavirin Treatment for Chronic Hepatitis C, Lancet 1991, 337:1058-91.
Reichard, O, et al, Hepatitis C Viral RNA Titers in Serum Prior to, During, and After Oral Treatment with Ribavirin for Chronic Hepatitis C, Journal of Medical Virology, 1993, 41:99-102.
Reziez, M, et al, Treatment of Hepatitis C Viral Infection (HCV) in the Transplanted Patie
Fish Robert D.
ICN Pharmaceuticals, Inc.
Owens Howard
Wilson James O.
LandOfFree
Specific modulation of Th1/Th2 cytokine expression by ribavirin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Specific modulation of Th1/Th2 cytokine expression by ribavirin , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific modulation of Th1/Th2 cytokine expression by ribavirin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-259022